< Back to latest news & events

Blogs

Plant Patent Infringement in the US Relies on Evidence of Asexual Reproduction

April 2025

A recent case in the US District Court for the Northern District of Texas (Dallas Division) once again highlights how important the initial pleadings and evidence in patent infringement cases can be.

The case is between David Austin Roses Ltd and GCM Ranch LLC[1] and is based on alleged willful infringement of US plant patents held by David Austin covering several varieties of roses, and corresponding trademark infringement. David Austin Roses Ltd is a major British rose breeding company. The varieties bred by David Austin are well known as the company has been established for a long time and consistently obtains PVR protection for its roses around the world, including under the US Plant Patent Act. They also typically file trademarks for the tradenames of each rose covered under a corresponding plant patent.

In this case, David Austin alleged that GCM Ranch infringed nine granted US plant patents by selling rose varieties that fall under the plant patent claims. However the evidence they provided in their pleadings was based mostly on screenshots of the rose products on the GCM Ranch websites resembling the patented varieties, and reviews indicating sale of the products to consumers.

In response, GCM Ranch argued that the evidence was not sufficient to prove patent infringement because David Austin failed to provide any explanation of how the alleged infringing plants were produced. According to USC 163, in the case of a plant patent, the grant shall ‘include the right to exclude others from asexually reproducing the plant, and from using, offering for sale, or selling the plant so reproduced, or any of its parts, throughout the United States’.  It was clear that David Austin demonstrated that the plant was being offered for sale and sold, but did not satisfy that said plants were proven to be asexually reproduced from the patented plant. GCM Ranch seized on this point of law in their response, as did the Court. Despite the striking similarities in the plants being sold to the protected varieties, and the agreement that GCM Ranch new of the plant patents at issue, the Court granted GCM Ranch’s motion to dismiss the plant patent infringement case. The Court stated that ‘even though the roses resemble one another, David Austin has failed to plausibly allege that GCM Ranch’s roses were asexually reproduced from David Austin’s roses. For example, David Austin did not allege how GCM Ranch was asexually reproducing the patented roses—i.e., whether they did so by grafting, budding, or layering’.

It is clear that for plant patent infringement in the US the pleadings must be sure to provide factual evidence of how the infringing plants were actually derived from the patented plant, in addition to evidence of sales of the infringing plants. It seems that simply alleging that the patented plant variety has been asexually reproduced is not enough. A full case should be presented at the pleadings stage to avoid surprising dismissal.

[1] https://archive.org/details/gov.uscourts.txnd.388559/gov.uscourts.txnd.388559.33.0.pdf


This post was written by Partner and Patent Attorney Punita Shah and Partner and Patent Attorney Ellie Purnell.

Latest updates

Doubling Up on Added Matter at the UPC

Following the UPC Court of Appeal (CoA) decision in Abbott v Sibio (APL_39664/2024, 14 February 2025) we now have a second CoA decision on added matter in expert Klein v …

Read article
Event - 4th November 2025

HGF are Silver Sponsors of LSPN Europe 2025

HGF is proud to be a Silver Sponsor of LSPN Europe 2025, a leading forum dedicated to helping life sciences innovators protect and leverage their intellectual property across the entire …

Event details
Event - 30th - 31st October 2025

RAPS European Digital Technologies and Software conference

HGF is proud to be attending the RAPS European Digital Technologies and Software conference in The Netherlands on 30th-31st October. HGF Partner and Patent Attorney Janine Swarbrick and Patent Director …

Event details

Protect It Before You Promote It: IP Advice for MedTech Innovators

Developed a new medical product? Check. Got tickets to an exciting MedTech conference to show off your new product? Check. Intellectual property? Pardon? In the excitement of bringing a new …

Read article

Agritech Thymes: The Bite of Implied Consent: Lessons from the Pink Lady Case

Can the supply of a plant variety without clear and defined restrictions on its use be an implicit consent to commercialise it? This case centres on the evidence required to …

Read article

IAM Global Leaders 2026

HGF is proud to announce that we have 3 partners listed as an IAM Global Leader 2026. To qualify for inclusion in the IAM Global Leaders, individuals must be ranked …

Read article

The Bite of Implied Consent: Lessons from the Pink Lady Case

A recent European Union court decision considers the issue of implied consent to commercialise a plant variety, and whether the evidence meets the threshold of “serious doubts” of the validity …

Read article
Event - 5th November 2025

HGF are Gold Sponsors of IAM Live: Navigating the UPC 2025

We’re excited to share that HGF is a Gold Sponsor of IAM Live: Navigating the UPC 2025, taking place on the 5th November at the Marriott Opera Ambassador Hotel in …

Event details